NIH Patents and Patent Applications

This list includes non-provisional and PCT patent filings.

CSV download of the complete patent data set.

For information on patent application codes, country codes, and patent status, see the Patents FAQ.

Tips:
Reset the Search Filters to go back to the initial display of all records.
Sort columns by clicking on the blue column headers.
The Search function searches across all columns.
To filter results by Lead IC, Country, or Application, type or use the dropdown menu.

Lead IC Reference Number Title Country Patent Application Type Application Number Date Filed Patent Number Date Issued Patent Status Patent PDF
NIAID E-120-2001-0-AU-91 Development of Mutations Useful for Attenuating Dengue Viruses and Chimeric Dengue Viruses AU DIV 2018200091 Expired
NIAID E-006-2017-0-PCT-02 LIVE ATTENUATED FLAVIRUS VACCINES AND METHODS OF USING AND MAKING SAME PCT PCT PCT/US2018/012346 Expired
NIAID E-015-2017-0-PCT-02 METHODS FOR THE DETECTION OF TAU PROTEIN AGGREGATES PCT PCT PCT/US2017/069024 Expired
NIAID E-015-2017-0-EP-04 METHODS FOR THE DETECTION OF TAU PROTEIN AGGREGATES EP National Stage 17835778.6 Pending
NIAID E-015-2017-0-CA-03 METHODS FOR THE DETECTION OF TAU PROTEIN AGGREGATES CA National Stage 3047132 Pending
NIA E-275-2011-0-US-16 METHOD FOR DIAGNOSING A NEURODEGENERATIVE DISEASE US CON 15/858,282 Pending
NCI E-193-2015-0-US-04 METHODS OF CHARACTERIZING ADRENOCORTICAL TUMORS US National Stage 15/740,577 Abandoned
NCI E-235-2015-0-JP-01 Methods for the Treatment of Kaposi's Sarcoma or KSHV-Induced Lymphoma Using Immunomodulatory Compounds, and Uses of Biomarkers JP National Stage 2017-567058 Pending
NIEHS E-292-2015-0-US-03 Methods And Composition For Treating Nephropathy US National Stage 15/739,718 Abandoned
NCI E-235-2015-0-EP-01 Methods for the Treatment of Kaposi's Sarcoma or KSHV-Induced Lymphoma Using Immunomodulatory Compounds, and Uses of Biomarkers EP National Stage 16 815375.7 Issued
NCI E-235-2015-0-SK-01 Methods for the Treatment of Kaposi's Sarcoma or KSHV-Induced Lymphoma Using Immunomodulatory Compounds, and Uses of Biomarkers SK EP 16815375.7 Issued
NCI E-235-2015-0-SI-01 Methods for the Treatment of Kaposi's Sarcoma or KSHV-Induced Lymphoma Using Immunomodulatory Compounds, and Uses of Biomarkers SI EP 16815375.7 Issued
NCI E-235-2015-0-HU-01 Methods for the Treatment of Kaposi's Sarcoma or KSHV-Induced Lymphoma Using Immunomodulatory Compounds, and Uses of Biomarkers HU EP 16815375.7 Issued
NCI E-235-2015-0-IE-01 Methods for the Treatment of Kaposi's Sarcoma or KSHV-Induced Lymphoma Using Immunomodulatory Compounds, and Uses of Biomarkers IE EP 16815375.7 Issued
NCI E-235-2015-0-IT-01 Methods for the Treatment of Kaposi's Sarcoma or KSHV-Induced Lymphoma Using Immunomodulatory Compounds, and Uses of Biomarkers IT EP 16815375.7 Issued
NCI E-235-2015-0-GR-01 Methods for the Treatment of Kaposi's Sarcoma or KSHV-Induced Lymphoma Using Immunomodulatory Compounds, and Uses of Biomarkers GR EP 16815375.7 Issued
NCI E-235-2015-0-CH-01 Methods for the Treatment of Kaposi's Sarcoma or KSHV-Induced Lymphoma Using Immunomodulatory Compounds, and Uses of Biomarkers CH EP 16815375.7 Issued
NCI E-235-2015-0-CZ-01 Methods for the Treatment of Kaposi's Sarcoma or KSHV-Induced Lymphoma Using Immunomodulatory Compounds, and Uses of Biomarkers CZ EP 16815375.7 Issued
NCI E-235-2015-0-AT-01 Methods for the Treatment of Kaposi's Sarcoma or KSHV-Induced Lymphoma Using Immunomodulatory Compounds, and Uses of Biomarkers AT EP 16815375.7 Issued
NCI E-014-2017-0-EP-05 HUMAN MONOCLONAL ANTIBODIES SPECIFIC FOR FLT3 AND USES THEREOF EP National Stage 17835904.8 Issued
NCI E-014-2017-0-GB-01 HUMAN MONOCLONAL ANTIBODIES SPECIFIC FOR FLT3 AND USES THEREOF GB EP 17835904.8 Issued
NCI E-014-2017-0-DE-01 HUMAN MONOCLONAL ANTIBODIES SPECIFIC FOR FLT3 AND USES THEREOF DE EP 17835904.8 Issued
NCI E-014-2017-0-FR-01 HUMAN MONOCLONAL ANTIBODIES SPECIFIC FOR FLT3 AND USES THEREOF FR EP 17835904.8 Issued
NIAID E-158-2007-3-US-05 LIVE ATTENUATED VIRUS VACCINES FOR LA CROSSE VIRUS AND OTHER BUNYAVIRIDAE US DIV 15/850,696 10206995 Abandoned PDF
NCI E-014-2017-0-PCT-02 HUMAN MONOCLONAL ANTIBODIES SPECIFIC FOR FLT3 AND USES THEREOF PCT PCT PCT/US2017/067974 Expired
NCI E-014-2017-0-EP-08 HUMAN MONOCLONAL ANTIBODIES SPECIFIC FOR FLT3 AND USES THEREOF EP DIV 22209293.4 Pending
NCI E-014-2017-0-AU-03 HUMAN MONOCLONAL ANTIBODIES SPECIFIC FOR FLT3 AND USES THEREOF AU National Stage 2017382883 Pending
NCI E-014-2017-0-CA-04 HUMAN MONOCLONAL ANTIBODIES SPECIFIC FOR FLT3 AND USES THEREOF CA National Stage 3045902 Pending
NCI E-230-2012-0-US-13 T CELL RECEPTORS RECOGNIZING MHC CLASS II-RESTRICTED MAGE-A3 US DIV 15/848,344 10611815 Issued PDF
NCI E-115-2017-0-PCT-02 Azaindenoisoquinoline Compounds and Uses Thereof PCT PCT PCT/US2017/067206 Expired
NCI E-115-2017-0-EP-05 Azaindenoisoquinoline Compounds and Uses Thereof EP National Stage 17882353.0 Pending
NCI E-115-2017-0-CA-03 Azaindenoisoquinoline Compounds and Uses Thereof CA National Stage 3047992 Pending
NCI E-115-2017-0-JP-06 Azaindenoisoquinoline Compounds and Uses Thereof JP National Stage 2019-534676 Pending
NLM E-110-2016-2-RU-08 Novel CRISPR Enzymes And Systems RU National Stage 2018101730 Issued
NLM E-111-2016-7-RU-08 Novel CRISPR Enzymes And Systems RU National Stage 2018101732 Issued
NCI E-188-2017-1-PCT-01 PEPTIDE HYDROGELS AND USE THEREOF PCT PCT PCT/US2017/066893 Expired
NCI E-115-2017-0-CN-04 Azaindenoisoquinoline Compounds and Uses Thereof CN National Stage 2017800830733 Issued
NLM E-111-2016-9-US-01 NOVEL CRISPR ENZYMES AND SYSTEMS US CIP 15/844,530 114212502 Issued PDF
NCI E-130-2011-0-US-21 HUMAN MONOCLONAL ANTIBODIES SPECIFIC FOR GLYPICAN-3 AND USE THEREOF US DIV 15/843,256 10640571 Issued PDF
NIAID E-174-2017-1-PCT-02 Protection Of Calves By A Prefusion-stabillze Bovine RSV Vaccine PCT PCT PCT/EP2017/083180 Expired
NIAID E-174-2017-1-EP-04 Protection Of Calves By A Prefusion-stabillze Bovine RSV Vaccine EP National Stage 17832216.0 Pending
NCI E-289-2011-0-RU-21 YEAST-MUC1 IMMUNOTHERAPY COMPOSITIONS AND USES THEREOF RU DIV 2017143985 Pending
NIAID E-174-2017-1-CA-03 Protection Of Calves By A Prefusion-stabillze Bovine RSV Vaccine CA National Stage 3043790 Pending
NLM E-110-2016-3-US-01 Novel CRISPR Enzymes And Systems US CIP 15/842,073 111807512 Issued PDF
NCI E-019-2017-0-PCT-02 SHARPIN-BASED POLYPEPTIDES AND THEIR USES PCT PCT PCT/US2017/66463 Expired
NCATS E-276-2011-0-AU-10 Compounds And Methods For The Prevention And Treatment Of Tumor Metastasis And Tumorgenesis AU DIV 2017276258 Issued
NCI E-250-2016-0-PCT-02 METHODS OF PREPARING AN ISOLATED OR PURIFIED POPULATION OF THYMIC EMIGRANT CELLS AND METHODS OF TREATMENT USING SAME PCT PCT PCT/US2017/65986 Expired
NIBIB E-143-2015-0-US-04 CHEMICAL CONJUGATES OF EVANS BLUE DERIVATIVES AND THEIR USE IN THE PRODUCTION OF LONG-ACTING THERAPEUTICS US National Stage 15/735,687 10709790 Issued PDF
NCI E-151-2011-0-US-05 REDUCTION OF TGF BETA SIGNALING IN MYELOID CELLS IN THE TREATMENT OF CANCER US DIV 15/837,905 Abandoned
NINDS E-130-2022-3-EP-01 OXABICYCLOHEPTANES FOR MODULATION OF IMMUNE RESPONSE EP National Stage 17879038.2 Issued